CD274 and non-small cell lung carcinoma: As shown in the PEMBRO-RT study, a significant clinical benefit was found in patients with metastatic NSCLC who had a PDL-1 expression > 0 yet < 49% that received combinatorial immunotherapy and radiation to the primary tumor.